ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.580
+0.150 (3.39%)
Feb 13, 2026, 4:08 PM HKT

HKG:1541 Ratios and Metrics

Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21
1,9762,10211,187--
Market Cap Growth
-3.54%-81.21%---
Enterprise Value
1,3731,65510,650--
Last Close Price
4.585.1629.90--
PS Ratio
14.6824.831319.67--
PB Ratio
3.382.9113.57--
P/TBV Ratio
3.372.9113.57--
EV/Sales Ratio
10.2019.561256.23--
Debt / Equity Ratio
0.290.200.100.02-0.01
Net Debt / Equity Ratio
-1.03-0.91-0.71-0.800.41
Net Debt / EBITDA Ratio
1.822.071.521.763.21
Net Debt / FCF Ratio
3.904.451.442.372.81
Asset Turnover
0.160.090.010.01-
Quick Ratio
3.293.515.2612.300.27
Current Ratio
3.334.045.9312.600.28
Return on Equity (ROE)
-53.53%-44.38%-49.68%--
Return on Assets (ROA)
-25.66%-21.43%-26.59%-26.29%-
Return on Capital Employed (ROCE)
-56.20%-43.50%-48.10%-46.20%13.30%
Earnings Yield
-16.78%-15.99%-3.74%--
FCF Yield
-7.81%-7.01%-3.65%--
Buyback Yield / Dilution
-6.17%-4.24%-9.05%-284.99%-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.